Blocking CGRP in migraine patients – a review of pros and cons

Marie Deen, Edvige Correnti, Katharina Kamm, Tim Kelderman, Laura Papetti, Eloisa Rubio-Beltrán, Simone Vigneri, Lars Edvinsson, Antoinette Maassen Van Den Brink, On behalf of the European Headache Federation School of Advanced Studies (EHF-SAS)

Research output: Contribution to journalReview article

Abstract

Migraine is the most prevalent neurological disorder worldwide and it has immense socioeconomic impact. Currently, preventative treatment options for migraine include drugs developed for diseases other than migraine such as hypertension, depression and epilepsy. During the last decade, however, blocking calcitonin gene-related peptide (CGRP) has emerged as a possible mechanism for prevention of migraine attacks. CGRP has been shown to be released during migraine attacks and it may play a causative role in induction of migraine attacks. Here, we review the pros and cons of blocking CGRP in migraine patients. To date, two different classes of drugs blocking CGRP have been developed: small molecule CGRP receptor antagonists (gepants), and monoclonal antibodies, targeting either CGRP or the CGRP receptor. Several trials have been conducted to test the efficacy and safety of these drugs. In general, a superior efficacy compared to placebo has been shown, especially with regards to the antibodies. In addition, the efficacy is in line with other currently used prophylactic treatments. The drugs have also been well tolerated, except for some of the gepants, which induced a transient increase in transaminases. Thus, blocking CGRP in migraine patients is seemingly both efficient and well tolerated. However, CGRP and its receptor are abundantly present in both the vasculature, and in the peripheral and central nervous system, and are involved in several physiological processes. Therefore, blocking CGRP may pose a risk in subjects with comorbidities such as cardiovascular diseases. In addition, long-term effects are still unknown. Evidence from animal studies suggests that blocking CGRP may induce constipation, affect the homeostatic functions of the pituitary hormones or attenuate wound healing. However, these effects have so far not been reported in human studies. In conclusion, this review suggests that, based on current knowledge, the pros of blocking CGRP in migraine patients exceeds the cons.

Original languageEnglish
Article number96
JournalJournal of Headache and Pain
Volume18
Issue number1
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

Calcitonin Gene-Related Peptide
Migraine Disorders
Calcitonin Gene-Related Peptide Receptors
Pharmaceutical Preparations
Physiological Phenomena
Pituitary Hormones
Peripheral Nervous System
Constipation
Transaminases
Nervous System Diseases
Wound Healing
Comorbidity
Epilepsy
Cardiovascular Diseases
Central Nervous System
Monoclonal Antibodies
Placebos
Hypertension
Safety
Antibodies

Keywords

  • Acute treatment
  • Cgrp
  • Cgrp receptor
  • Gepants
  • Migraine
  • Prophylactic treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

Deen, M., Correnti, E., Kamm, K., Kelderman, T., Papetti, L., Rubio-Beltrán, E., ... On behalf of the European Headache Federation School of Advanced Studies (EHF-SAS) (2017). Blocking CGRP in migraine patients – a review of pros and cons. Journal of Headache and Pain, 18(1), [96]. https://doi.org/10.1186/s10194-017-0807-1

Blocking CGRP in migraine patients – a review of pros and cons. / Deen, Marie; Correnti, Edvige; Kamm, Katharina; Kelderman, Tim; Papetti, Laura; Rubio-Beltrán, Eloisa; Vigneri, Simone; Edvinsson, Lars; Maassen Van Den Brink, Antoinette; On behalf of the European Headache Federation School of Advanced Studies (EHF-SAS).

In: Journal of Headache and Pain, Vol. 18, No. 1, 96, 01.12.2017.

Research output: Contribution to journalReview article

Deen, M, Correnti, E, Kamm, K, Kelderman, T, Papetti, L, Rubio-Beltrán, E, Vigneri, S, Edvinsson, L, Maassen Van Den Brink, A & On behalf of the European Headache Federation School of Advanced Studies (EHF-SAS) 2017, 'Blocking CGRP in migraine patients – a review of pros and cons', Journal of Headache and Pain, vol. 18, no. 1, 96. https://doi.org/10.1186/s10194-017-0807-1
Deen, Marie ; Correnti, Edvige ; Kamm, Katharina ; Kelderman, Tim ; Papetti, Laura ; Rubio-Beltrán, Eloisa ; Vigneri, Simone ; Edvinsson, Lars ; Maassen Van Den Brink, Antoinette ; On behalf of the European Headache Federation School of Advanced Studies (EHF-SAS). / Blocking CGRP in migraine patients – a review of pros and cons. In: Journal of Headache and Pain. 2017 ; Vol. 18, No. 1.
@article{20cdf46472414cbf926aa1caa6cbdb23,
title = "Blocking CGRP in migraine patients – a review of pros and cons",
abstract = "Migraine is the most prevalent neurological disorder worldwide and it has immense socioeconomic impact. Currently, preventative treatment options for migraine include drugs developed for diseases other than migraine such as hypertension, depression and epilepsy. During the last decade, however, blocking calcitonin gene-related peptide (CGRP) has emerged as a possible mechanism for prevention of migraine attacks. CGRP has been shown to be released during migraine attacks and it may play a causative role in induction of migraine attacks. Here, we review the pros and cons of blocking CGRP in migraine patients. To date, two different classes of drugs blocking CGRP have been developed: small molecule CGRP receptor antagonists (gepants), and monoclonal antibodies, targeting either CGRP or the CGRP receptor. Several trials have been conducted to test the efficacy and safety of these drugs. In general, a superior efficacy compared to placebo has been shown, especially with regards to the antibodies. In addition, the efficacy is in line with other currently used prophylactic treatments. The drugs have also been well tolerated, except for some of the gepants, which induced a transient increase in transaminases. Thus, blocking CGRP in migraine patients is seemingly both efficient and well tolerated. However, CGRP and its receptor are abundantly present in both the vasculature, and in the peripheral and central nervous system, and are involved in several physiological processes. Therefore, blocking CGRP may pose a risk in subjects with comorbidities such as cardiovascular diseases. In addition, long-term effects are still unknown. Evidence from animal studies suggests that blocking CGRP may induce constipation, affect the homeostatic functions of the pituitary hormones or attenuate wound healing. However, these effects have so far not been reported in human studies. In conclusion, this review suggests that, based on current knowledge, the pros of blocking CGRP in migraine patients exceeds the cons.",
keywords = "Acute treatment, Cgrp, Cgrp receptor, Gepants, Migraine, Prophylactic treatment",
author = "Marie Deen and Edvige Correnti and Katharina Kamm and Tim Kelderman and Laura Papetti and Eloisa Rubio-Beltr{\'a}n and Simone Vigneri and Lars Edvinsson and {Maassen Van Den Brink}, Antoinette and {On behalf of the European Headache Federation School of Advanced Studies (EHF-SAS)}",
year = "2017",
month = "12",
day = "1",
doi = "10.1186/s10194-017-0807-1",
language = "English",
volume = "18",
journal = "Journal of Headache and Pain",
issn = "1129-2369",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Blocking CGRP in migraine patients – a review of pros and cons

AU - Deen, Marie

AU - Correnti, Edvige

AU - Kamm, Katharina

AU - Kelderman, Tim

AU - Papetti, Laura

AU - Rubio-Beltrán, Eloisa

AU - Vigneri, Simone

AU - Edvinsson, Lars

AU - Maassen Van Den Brink, Antoinette

AU - On behalf of the European Headache Federation School of Advanced Studies (EHF-SAS)

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Migraine is the most prevalent neurological disorder worldwide and it has immense socioeconomic impact. Currently, preventative treatment options for migraine include drugs developed for diseases other than migraine such as hypertension, depression and epilepsy. During the last decade, however, blocking calcitonin gene-related peptide (CGRP) has emerged as a possible mechanism for prevention of migraine attacks. CGRP has been shown to be released during migraine attacks and it may play a causative role in induction of migraine attacks. Here, we review the pros and cons of blocking CGRP in migraine patients. To date, two different classes of drugs blocking CGRP have been developed: small molecule CGRP receptor antagonists (gepants), and monoclonal antibodies, targeting either CGRP or the CGRP receptor. Several trials have been conducted to test the efficacy and safety of these drugs. In general, a superior efficacy compared to placebo has been shown, especially with regards to the antibodies. In addition, the efficacy is in line with other currently used prophylactic treatments. The drugs have also been well tolerated, except for some of the gepants, which induced a transient increase in transaminases. Thus, blocking CGRP in migraine patients is seemingly both efficient and well tolerated. However, CGRP and its receptor are abundantly present in both the vasculature, and in the peripheral and central nervous system, and are involved in several physiological processes. Therefore, blocking CGRP may pose a risk in subjects with comorbidities such as cardiovascular diseases. In addition, long-term effects are still unknown. Evidence from animal studies suggests that blocking CGRP may induce constipation, affect the homeostatic functions of the pituitary hormones or attenuate wound healing. However, these effects have so far not been reported in human studies. In conclusion, this review suggests that, based on current knowledge, the pros of blocking CGRP in migraine patients exceeds the cons.

AB - Migraine is the most prevalent neurological disorder worldwide and it has immense socioeconomic impact. Currently, preventative treatment options for migraine include drugs developed for diseases other than migraine such as hypertension, depression and epilepsy. During the last decade, however, blocking calcitonin gene-related peptide (CGRP) has emerged as a possible mechanism for prevention of migraine attacks. CGRP has been shown to be released during migraine attacks and it may play a causative role in induction of migraine attacks. Here, we review the pros and cons of blocking CGRP in migraine patients. To date, two different classes of drugs blocking CGRP have been developed: small molecule CGRP receptor antagonists (gepants), and monoclonal antibodies, targeting either CGRP or the CGRP receptor. Several trials have been conducted to test the efficacy and safety of these drugs. In general, a superior efficacy compared to placebo has been shown, especially with regards to the antibodies. In addition, the efficacy is in line with other currently used prophylactic treatments. The drugs have also been well tolerated, except for some of the gepants, which induced a transient increase in transaminases. Thus, blocking CGRP in migraine patients is seemingly both efficient and well tolerated. However, CGRP and its receptor are abundantly present in both the vasculature, and in the peripheral and central nervous system, and are involved in several physiological processes. Therefore, blocking CGRP may pose a risk in subjects with comorbidities such as cardiovascular diseases. In addition, long-term effects are still unknown. Evidence from animal studies suggests that blocking CGRP may induce constipation, affect the homeostatic functions of the pituitary hormones or attenuate wound healing. However, these effects have so far not been reported in human studies. In conclusion, this review suggests that, based on current knowledge, the pros of blocking CGRP in migraine patients exceeds the cons.

KW - Acute treatment

KW - Cgrp

KW - Cgrp receptor

KW - Gepants

KW - Migraine

KW - Prophylactic treatment

UR - http://www.scopus.com/inward/record.url?scp=85029912523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029912523&partnerID=8YFLogxK

U2 - 10.1186/s10194-017-0807-1

DO - 10.1186/s10194-017-0807-1

M3 - Review article

AN - SCOPUS:85029912523

VL - 18

JO - Journal of Headache and Pain

JF - Journal of Headache and Pain

SN - 1129-2369

IS - 1

M1 - 96

ER -